Novartis' Scemblix Obtains European Approval for the Treatment of Chronic Myeloid Leukemia

Longeveron Inc. LGVN announced that the European Patent Office (EPO) has published a notice of its intention to grant the company a patent (EP application no. 15861319.0) relating to methods for treating endothelial dysfunction and monitoring the effectiveness of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells (MSCs). The cells are delivered to patients with cardiovascular disease through monitoring of a protein, vascular endothelial growth factor (VEGF), which is a signal protein produced by many cells that stimulate blood vessel formation.

>

"We are extremely pleased to receive this notice from the European Patent Office," said Chris Min, M.D., Ph.D., Acting Chief Executive Officer and Chief Medical Officer at Longeveron. "This patent will strengthen our strong intellectual property portfolio and support our goal of providing effective cell therapies for a range of age-related and life-threatening conditions."

Now that the European Patent Office has issued an Intent to Grant, Longeveron will wait for the patent to be granted and then begin the patent registration process in a number of EU member countries. 'European Patent Organisation. In the jurisdictions where the patent is registered, the patent is expected to expire in November 2035.

Image from Shutterstock

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investment advice.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.